Revenue Performance - Revenue for Q3 2024 was $994.2 million, representing a 2% year-over-year growth on a reported basis and 3% on an organic basis[2]. - Total revenue for Q3 2024 was $994.2 million, a 2% increase from $975.0 million in Q3 2023[14]. - U.S. revenue decreased by 2%, while international revenue increased by 12% on a reported basis and 16% on an organic basis year-over-year[2]. - U.S. revenue decreased by 2% year-over-year to $701.9 million, while international revenue increased by 12% to $292.3 million[14]. - Sensor and other revenue grew by 9% year-over-year to $951.8 million, representing 96% of total revenue[15]. Income and Profitability - GAAP operating income was $152.0 million, or 15.3% of revenue, a decrease of 580 basis points compared to Q3 2023; Non-GAAP operating income was $212.0 million, or 21.3% of revenue, down 320 basis points year-over-year[2][5]. - GAAP net income for Q3 2024 was $134.6 million, or $0.34 per diluted share, compared to $120.7 million, or $0.29 per diluted share in Q3 2023[6]. - Net income for Q3 2024 increased to $134.6 million, compared to $120.7 million in Q3 2023[16]. - Basic net income per share rose to $0.34 from $0.31 year-over-year[16]. - Non-GAAP net income for Q3 2024 was $179.9 million, down from $202.8 million in Q3 2023[16]. - Adjusted EBITDA for Q3 2024 was $300.1 million, compared to $314.5 million in Q3 2023[16]. - GAAP net income for the three months ended September 30, 2024, was $134.6 million, up from $120.7 million for the same period in 2023, representing a 16.2% increase[17]. - Non-GAAP net income for the three months ended September 30, 2024, was $179.9 million, compared to $202.8 million in the prior year, reflecting a decrease of 11.3%[17]. - GAAP diluted net income per share for the three months ended September 30, 2024, was $0.34, an increase from $0.29 in the same quarter of 2023[17]. - Non-GAAP diluted net income per share for the three months ended September 30, 2024, was $0.45, down from $0.50 in the prior year, a decline of 10%[17]. - The company reported a GAAP net income of $424.5 million for the nine months ended September 30, 2024, compared to $285.2 million for the same period in 2023, marking a significant increase of 48.8%[17]. - Non-GAAP net income for the nine months ended September 30, 2024, was $482.4 million, up from $410.7 million in the previous year, indicating a growth of 17.5%[17]. Expenses and Financial Flexibility - Research and development expenses increased to $135.4 million, up from $131.4 million in Q3 2023[16]. - Total operating expenses for Q3 2024 were $441.8 million, compared to $417.8 million in Q3 2023[16]. - Cash and cash equivalents as of September 30, 2024, totaled $2.49 billion, providing significant financial flexibility for market expansion[7]. - The company incurred a nonrecurring $24.6 million non-cash inventory build charge and rent for vacated office space in San Diego, California, impacting the financial results for the three months ended September 30, 2024[17]. Product Development and Guidance - Launched Stelo, the first over-the-counter glucose biosensor in the U.S., targeting adults with prediabetes and type 2 diabetes not on insulin therapy[2]. - The company submitted the Dexcom G7 15-day CGM system to the FDA for review after the quarter ended[2]. - Dexcom is reiterating its 2024 revenue guidance of approximately $4.00 - 4.05 billion, indicating an expected organic growth of 11% to 13%[3]. Metrics and Adjustments - Non-GAAP gross profit margin for Q3 2024 was approximately 63.0%, down from 64.7% in Q3 2023[5]. - Adjustments related to taxes for the nine months ended September 30, 2024, were primarily due to the tax effect of non-GAAP adjustments and excess tax benefits from share-based compensation[18]. - The company emphasizes the importance of organic revenue as a metric for consistent comparison of revenue to prior periods and industry peers, excluding non-CGM revenue acquired or divested in the trailing twelve months[22].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against DexCom, Inc. regarding a class action complaint filed due to alleged breaches of fiduciary duties by the board of directors [1] Financial Performance - On July 25, 2024, DexCom announced its Q2 fiscal 2024 financial results and reduced its revenue guidance for the full fiscal year 2024, attributing the results to the execution of several key strategic initiatives that did not meet their standards [2] - Following the announcement, DexCom's stock price plummeted from $107.85 per share on July 25, 2024, to $64.00 per share on July 26, 2024, marking a decline of approximately 40.66% in just one day [2]

DexCom, Inc. (DXCM) is scheduled to release third-quarter 2024 results on Oct. 24, after the closing bell. In the last reported quarter, the company’s earnings beat estimates by 10.26%.The bottom line also outpaced the consensus mark in each of the trailing four quarters, delivering an average surprise of 23.03%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q3 EstimatesCurrently, the Zacks Consensus Estimate for revenues is pegged at $991.6 million, indicating growth of 1.7% from ...

Core Insights - DexCom (DXCM) is expected to report quarterly earnings of $0.43 per share, a decline of 14% year-over-year, with revenues forecasted at $991.55 million, reflecting a 1.7% increase compared to the previous year [1] - The consensus EPS estimate has been adjusted downward by 0.4% over the past 30 days, indicating a reassessment by analysts [1] Revenue Estimates - Analysts predict 'Revenue- Hardware' will reach $49.44 million, representing a significant decline of 51.2% from the year-ago quarter [2] - 'Revenue- Sensor and other' is expected to be $941.35 million, indicating a year-over-year increase of 7.7% [2] - 'Revenue- United States' is forecasted to be $719.01 million, reflecting a slight increase of 0.8% from the previous year [2] - 'Revenue- International' is estimated to reach $265.16 million, showing a year-over-year growth of 1.4% [3] Stock Performance - DexCom shares have increased by 2.8% over the past month, while the Zacks S&P 500 composite has moved up by 4.5% [3] - With a Zacks Rank 4 (Sell), DexCom is anticipated to underperform the overall market in the near future [3]

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline. SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly misleading investors regarding its sales force expansion strategy and its impact on customer growth and market share [1][2]. Group 1: Allegations Against DexCom - The lawsuit claims that DexCom's sales force expansion strategy led to slow customer growth [2] - It is alleged that this strategy undermined relationships with durable medical equipment (DME) distributors, which are crucial for revenue generation [2] - The deteriorating relationships with DME distributors reportedly caused DexCom to lose significant market share to competitors [2] - As a result of these issues, statements made by DexCom during the Class Period about its business and operations were deemed false and misleading [2] Group 2: Lead Plaintiff Process - Investors in DexCom have until October 21, 2024, to seek appointment as a lead plaintiff representative in the class action [3] - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3] - The lead plaintiff selects counsel to represent the class, and this decision does not affect the ability of other investors to share in any recovery [3] Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages affected investors to contact them for more information [4][5] - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5]

Recent developments might have scared away some investors, but patience could pay off.Over the past five years, diabetes-focused medical device specialist DexCom (DXCM -0.50%) has made meaningful progress on several fronts. The company launched new products in the continuous glucose monitoring (CGM) niche and entered new geographies. Its revenue has generally increased at a good pace on a year-over-year basis.However, after a recent plunge, DexCom has underperformed the S&P 500 in the past half-decade. Can ...

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the DexCom class action lawsuit – captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.) – charges DexCom, Inc. (NASDAQ: DXCM) and certain of DexCom’s top executives with violations of the Securities Exchange Act of 1934. Subsequently filed complaints are captioned Oakland County Employees’ Retirement System v. DexCom, Inc., No. 24-cv-01804 (S.D. Cal.), and Carnes v. DexCom, Inc., No. 24-cv-01809 (S.D. Cal.). ...

Wall Street expects a year-over-year decline in earnings on higher revenues when DexCom (DXCM) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on October 24, 2024, might help the stock move higher if these key numbers are better than expec ...